Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Early immune responses linked to protective HIV antibodies

    Developing an effective HIV vaccine remains one of the major challenges in global health. One promising approach focuses on so-called broadly neutralizing antibodies, antibodies that can block many different variants of HIV. However, only a small fraction of people living with the virus develop these antibodies naturally.

  • New Prior Intimation Rule for Drug Export Trials to Take Effect from April 21

    In a regulatory update aimed at streamlining drug export processes, the Central Drugs Standard Control Organization (CDSCO) has announced the implementation of a Prior Intimation System for Form CT-05 applications. The new system will come into force from April 21, 2026, following amendments introduced under Gazette Notification G.S.R. 50(E).

  • Pharma Innovation Gets a Boost as NIPER Mohali Joins Hands with Novartis

    In a significant move to strengthen India’s pharmaceutical research ecosystem, the National Institute of Pharmaceutical Education and Research (NIPER), Mohali has signed an agreement with Novartis Healthcare Private Limited. The collaboration aims to promote innovation and deepen industry-academia partnerships in the country.

  • New Hope for COPD Patients as AstraZeneca Drug Shows Strong Results in Major Trial

    A new experimental drug from AstraZeneca is giving fresh hope to millions of people living with Chronic Obstructive Pulmonary Disease after showing positive results in a large late-stage study.

    The drug, Tozorakimab, met its main goal in the Phase III MIRANDA trial. It helped reduce the number of serious flare-ups, also called exacerbations, in patients who were already taking standard inhaled treatments but still had symptoms.

  • Piramal Critical Care has successfully closed the acquisition of Kenalog
    Kenalog® is a well-established injectable therapy with a long-standing legacy in the treatment of inflammatory conditions, marketed across 15 countries under trusted brands including Kenalog®, Kenacort®, Trigon®, and Adcortyl®.
  • Eli Lilly announced results of Jaypirca (pirtobrutinib)

    Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy until their disease progresses. 

  • Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

    Johnson & Johnson today announced favorable 12-month interim effectiveness and safety results from VARIPURE, the largest prospective post-market follow-up study evaluating first-time pulsed field ablation (PFA) using the VARIPULSE Platform. The data were presented at the PFA Summit during the 2026 European Heart Rhythm Association (EHRA) Annual Meeting in Paris and simultaneously published in Europace.

  • Connect, Present, and Inspire for Students, Research Scholars, and Academicians

    The Department of Pharmacy Practice, SIMATS College of Pharmacy, Chennai, in collaboration with the Indian Pharmaceutical Association (IPA) and IPA Tamil Nadu State Branch, successfully conducted a Five-Day Virtual Poster Showcase (VPS 2026) from April 6–10, 2026. The event, held via Google Meet, aimed to promote research aptitude and scientific communication among students and early-career academicians.

  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA
    Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.
  • Amgen announced results from a Phase 3 trial of TEPEZZA
    Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease
Subscribe to Pharma News